Health Affairs, 24, no. 3 (2005): 666-679 doi: 10.1377/hlthaff.24.3.666 © 2005 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Lieu, T. A. Articles by Hinman, A. R. Search for Related Content PubMed PubMed Citation Articles by Lieu, T. A. Articles by Hinman, A. R. Related Collections Consumer Issues Health Promotion/Disease Prevention International Issues Vaccines Public Health Research And Technology

Financing

Overcoming Economic Barriers To The Optimal Use Of Vaccines

Vaccines are among the most cost-effective interventions in health care, but economic factors may interfere with their optimal development and delivery in both industrialized and developing countries. For the United States, making the best use of available vaccines will require increasing the financing for vaccines via the public and private systems. For developing countries, innovative and promising approaches include pull mechanisms to establish predictable demand and push mechanisms such as targeted development programs. Partnerships between philanthropy and public resources have made progress in addressing gaps in vaccine financing and development for developing countries, but much remains to be done.

                      What's this?

This article has been cited by other articles:

				S. W. Roush, T. V. Murphy, and and the Vaccine-Preventable Disease Table Working Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States JAMA, November 14, 2007; 298(18): 2155 - 2163. [Abstract] [Full Text] [PDF]

				E. G. Cohn Including Marginalized Populations in HIV Clinical Trials: A New Role for Nurse-Researchers Policy Politics Nursing Practice, November 1, 2007; 8(4): 271 - 275. [Abstract] [PDF]

				M. M. Mello and T. A. Brennan Legal Concerns and the Influenza Vaccine Shortage JAMA, October 12, 2005; 294(14): 1817 - 1820. [Full Text] [PDF]